Eli Lilly Says Japan Has Approved Kisunla (Donanemab-azbt, 350 Mg/20 mL Every Four Weeks Injection For IV Infusion) For Early Symptomatic Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly announced that Japan has approved its drug Kisunla (Donanemab-azbt) for early symptomatic Alzheimer's disease. The approval was based on data from the TRAILBLAZER-ALZ 2 Phase 3 clinical study.
September 24, 2024 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's drug Kisunla has been approved in Japan for treating early symptomatic Alzheimer's disease, potentially boosting its market presence and revenues.
The approval of Kisunla in Japan represents a significant regulatory milestone for Eli Lilly, likely enhancing its market presence in the Alzheimer's treatment space. This could lead to increased revenues from the Japanese market, positively impacting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90